表紙
市場調查報告書
商品編碼
1021333

非侵入性液態切片的全球市場 (2021-2031年):市場預測 (各提供區分、檢體、用途、技術、終端用戶)、各國資料 (16個國家)、競爭環境

Global Non-Invasive Liquid Biopsy Market: Focus on Offering, Sample, Application, Technology, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

出版日期: | 出版商: BIS Research Inc. | 英文 249 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球非侵入性液態切片的市場規模在預測期間內預計以20.38%的年複合成長率發展,成長到2031年94億7000萬美元規模。

全球的癌症罹患率上升,政府的醫療費津貼增加,患者偏好非侵入性的癌症診斷的趨勢,腫瘤學的生態系統的精密醫療的重要性高漲等要素促進該市場的成長。

本報告提供全球非侵入性液態切片的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律規章、償付環境,市場規模的變化、預測,提供區分、檢體、用途、技術、終端用戶、地區等各種區分的明細,競爭環境,市場佔有率,主要企業簡介等彙整資訊。

第1章 產品定義

第2章 市場範圍

第3章 調查手法

第4章 市場概要

  • 市場定義
  • 非侵入性液態切片的新的應用
  • 市場足跡、成長可能性
  • COVID-19的影響

第5章 產業分析

  • 概要
  • 美國的法律必要條件、組成架構
  • 歐洲的法律上的必要條件、組成架構
  • 亞太地區的法律上的必要條件、組成架構
  • 償付分析
  • RoI分析

第6章 市場動態

  • 概要
  • 影響分析
  • 市場推動要素
  • 阻礙市場要素
  • 市場機會

第7章 競爭情形

  • 聯盟、合作
  • 產品的認證
  • 產品銷售
  • 收購
  • 資金籌措、其他的活動
  • 市場佔有率分析
  • 價格分析

第8章 市場分析、預測:各提供種類

  • 產品
    • 套件
    • 化驗
  • 服務

第9章 市場分析、預測:各檢體

  • 便
  • 尿
  • 唾液
  • 其他

第10章 市場分析、預測:各用途

  • 腫瘤
  • 生殖健康
  • 代謝障礙
  • 其他

第11章 市場分析、預測:各技術

  • 聚合酵素鏈鎖反應(PCR)
    • 即時PCR(RT-PCR)
    • 數位PCR(dPCR)
  • 序列
    • 次世代定序(NGS)
    • Sanger定序
  • 微陣列
  • 其他

第12章 市場分析、預測:各終端用戶

  • 醫院、診斷實驗室
  • 學術、研究機關
  • 其他

第13章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區

第14章 企業簡介

  • Bio-Techne Corporation
  • Endress+Hauser Group
  • Exact Sciences Corporation
  • Lonza Group AG
  • MDxHealth
  • Merck KGaA
  • MutantDx
  • Norgen Biotek Corp
  • Nucleix Ltd.
  • Oasis Diagnostics Corporation
  • OraSure Technologies, Inc.
  • PerkinElmer Inc.
  • Predicine, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corporation
目錄
Product Code: BHP1090SA

“Global Non-Invasive Liquid Biopsy Market to Reach $9.47 Billion by 2031.”

Market Report Coverage - Non-Invasive Liquid Biopsy

Market Segmentation

  • Offering - Products (Kits and Assays) and Services
  • Sample - Stool, Urine, Saliva, and Other Samples
  • Application - Oncology, Reproductive Health, Metabolic Disorders, and Other Applications
  • Technology - Polymerase Chain Reaction (RT-PCR and dPCR), Sequencing (NGS and Sanger Sequencing), Microarray, and Other Technologies
  • End User - Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Other End Users

Regional Segmentation

  • North America - U.S., and Canada
  • Europe - Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Global Increase in Cancer Prevalence
  • Increasing Government Funding for Healthcare
  • Rise in Patient Preference for Non-Invasive Cancer Diagnosis
  • Growing Prominence of Precision Medicine in the Oncology Ecosystem

Market Challenges

  • False Negatives and Positives
  • Lack of Favorable Reimbursement Policies
  • Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies

Market Opportunities

  • Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy
  • Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets

Key Companies Profiled

Bio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Zymo Research Corporation.

Key Questions Answered in this Report:

  • How is non-invasive liquid biopsy revolutionizing the field of oncology, reproductive health, and metabolic disorders?
  • What are the major market drivers, challenges, and opportunities in the global non-invasive liquid biopsy market?
  • What are the underlying structures resulting in the emerging trends within the global non-invasive liquid biopsy market?
  • How did the COVID-19 pandemic impact the global non-invasive liquid biopsy ecosystem?
  • What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of non-invasive liquid biopsy?
  • What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
    • Offering (products and services)
    • Sample (stool, urine, saliva, and other samples)
    • Technology (sequencing, polymerase chain reaction (PCR), microarray, and other technologies)
    • Application (oncology, reproductive health, metabolic disorders, and other applications)
    • End User (academic and research institutions, hospitals and diagnostic laboratories, and other end users)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the non-invasive liquid biopsy companies in the region of their operation?
  • Who are the leading players with significant offerings in the global non-invasive liquid biopsy market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Our healthcare experts have found the non-invasive liquid biopsy industry to be one of the most rapidly evolving and dynamic markets, and the global market for non-invasive liquid biopsy is predicted to grow at a CAGR of 20.38% over the forecast period 2021-2031. The market is driven by certain factors, which include a global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.

The market is favored by the developments in the field of cancer molecular diagnostic testing and its attributes such as non-invasive liquid biopsy. Currently, the non-invasive liquid biopsy industry is witnessing an upsurge due to the global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.

Furthermore, biotechnology companies are focusing on the development of robust non-invasive liquid biopsy solutions for a wide range of applications, including oncology, reproductive health, metabolic disorders, to support clinicians to unravel insights pertaining to the analysis of genetic alterations present in the circulating biomarkers in samples such as stool, urine, and saliva. The development of non-invasive liquid biopsy products and services enabled clinicians to offer early cancer screening and diagnosis to patients, further improving survival rates.

Within the research report, the market is segmented on the basis of offering, sample, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies to further invest in the development of innovative cancer diagnostics, including non-invasive liquid biopsy, further aiding physicians to offer value-based clinical outcomes to patients. Due to the established presence of Exact Sciences Corporation in the U.S. market, offering its proprietary Cologuard test, the company has been the leading player in the non-invasive liquid biopsy ecosystem.

On the basis of region, North America holds the largest share of the non-invasive liquid biopsy market due to high infusion of funding from the government organizations for conducting cancer research, increasing prevalence of cancer, presence of market juggernauts in the region, growing awareness about non-invasive liquid biopsy products, and increasing awareness about early cancer screening. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

Table of Contents

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Non-Invasive Liquid Biopsy Market: Research Methodology
  • 3.2 Data Sources
    • 3.2.1 Primary Data Sources
    • 3.2.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Criteria for Company Profiling

4 Market Overview

  • 4.1 Market Definition
  • 4.2 Emerging Applications of Non-Invasive Liquid Biopsy
  • 4.3 Market Footprint and Growth Potential, $Million, 2020-2031
  • 4.4 COVID-19 Impact on the Global Non-Invasive Liquid Biopsy Market

5 Industry Analysis

  • 5.1 Overview
  • 5.2 Legal Requirements and Framework in the U.S.
    • 5.2.1 FDA Regulation
    • 5.2.2 CMS Regulation
  • 5.3 Legal Requirements and Frameworks in Europe
  • 5.4 Legal Requirements and Frameworks in Asia-Pacific
    • 5.4.1 China
    • 5.4.2 Japan
  • 5.5 Reimbursement Analysis
  • 5.6 Return on Investment (RoI) Analysis

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Market Drivers
    • 6.3.1 Global Increase in Cancer Prevalence
    • 6.3.2 Increasing Government Funding for Healthcare
    • 6.3.3 Rise in Patient Preference for Non-Invasive Cancer Diagnosis
    • 6.3.4 Growing Prominence of Precision Medicine in the Oncology Ecosystem
  • 6.4 Market Restraints
    • 6.4.1 False Negatives and Positives
    • 6.4.2 Lack of Favorable Reimbursement Policies
    • 6.4.3 Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies
  • 6.5 Market Opportunities
    • 6.5.1 Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy
    • 6.5.2 Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets

7 Competitive Landscape

  • 7.1 Synergistic Activities
  • 7.2 Product Approvals
  • 7.3 Product Launches
  • 7.4 Acquisitions
  • 7.5 Funding and Other Activities
  • 7.6 Market Share Analysis, 2019-2020
  • 7.7 Growth-Share Analysis
    • 7.7.1 Growth-Share Analysis (by Company)
    • 7.7.2 Growth-Share Analysis (by Technology)
    • 7.7.3 Growth-Share Analysis (by Application)
  • 7.8 Pricing Analysis
    • 7.8.1 Price with Sample Type

8 Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020-2031

  • 8.1 Overview
  • 8.2 Offering
    • 8.2.1 Kits
    • 8.2.2 Assays
  • 8.3 Services

9 Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2021-2031

  • 9.1 Overview
  • 9.2 Stool
  • 9.3 Urine
  • 9.4 Saliva
  • 9.5 Other Samples

10 Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031

  • 10.1 Overview
  • 10.2 Oncology
  • 10.3 Reproductive Health
  • 10.4 Metabolic Disorders
  • 10.5 Other Applications

11 Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020-2031

  • 11.1 Overview
  • 11.2 Polymerase Chain Reaction (PCR)
    • 11.2.1 Real-Time PCR (RT-PCR)
    • 11.2.2 Digital PCR (dPCR)
  • 11.3 Sequencing
    • 11.3.1 Next-Generation Sequencing (NGS)
    • 11.3.2 Sanger Sequencing
  • 11.4 Microarray
  • 11.5 Other Technologies

12 Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020-2031

  • 12.1 Overview
  • 12.2 Hospitals and Diagnostic Laboratories
  • 12.3 Academic and Research Institutions
  • 12.4 Other End Users

13 Global Non-Invasive Liquid Biopsy Market (by Region), $Million, 2020-2031

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
    • 13.2.2 Canada
    • 13.2.3 North America Non-Invasive Liquid Biopsy Market (by Application)
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 U.K.
    • 13.3.3 France
    • 13.3.4 Italy
    • 13.3.5 Spain
    • 13.3.6 Netherlands
    • 13.3.7 Rest-of-Europe
    • 13.3.8 Europe Non-Invasive Liquid Biopsy Market (by Application)
  • 13.4 Asia-Pacific (APAC)
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 India
    • 13.4.4 South Korea
    • 13.4.5 Australia
    • 13.4.6 Singapore
    • 13.4.7 Rest-of-Asia-Pacific (RoAPAC)
    • 13.4.8 Asia-Pacific Non-Invasive Liquid Biopsy Market (by Application)
  • 13.5 Latin America (LATAM)
    • 13.5.1 Brazil
    • 13.5.2 Mexico
    • 13.5.3 Rest-of-Latin America (RoLA)
    • 13.5.4 Latin America Non-Invasive Liquid Biopsy Market (by Application)
  • 13.6 Rest-of-the-World
    • 13.6.1 Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application)

14 Company Profiles

  • 14.1 Overview
  • 14.2 Bio-Techne Corporation
    • 14.2.1 Company Overview
    • 14.2.2 Role of Bio-Techne Corporation in the Global Non-Invasive Liquid Biopsy Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights About Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 Endress + Hauser Group
    • 14.3.1 Company Overview
    • 14.3.2 Role of Endress + Hauser Group in the Global Non-Invasive Liquid Biopsy Market
    • 14.3.3 Financials
    • 14.3.4 Key Insights About Financial Health of the Company
    • 14.3.5 SWOT Analysis
  • 14.4 Exact Sciences Corporation
    • 14.4.1 Company Overview
    • 14.4.2 Role of Exact Sciences Corporation in the Global Non-invasive Liquid Biopsy Market
    • 14.4.3 Financials
    • 14.4.4 Key Insights About Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 Lonza Group AG
    • 14.5.1 Company Overview
    • 14.5.2 Role of Lonza Group AG in the Global Non-Invasive Liquid Biopsy Market
    • 14.5.3 Financials
    • 14.5.4 Key Insights About Financial Health of the Company
    • 14.5.5 SWOT Analysis
  • 14.6 MDxHealth
    • 14.6.1 Company Overview
    • 14.6.2 Role of MDxHealth in the Global Non-Invasive Liquid Biopsy Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights About Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 Merck KGaA
    • 14.7.1 Company Overview
    • 14.7.2 Role of Merck KGaA in the Global Non-Invasive Liquid Biopsy Market
    • 14.7.3 Financials
    • 14.7.4 Key Insights About Financial Health of the Company
    • 14.7.5 SWOT Analysis
  • 14.8 MutantDx
    • 14.8.1 Company Overview
    • 14.8.2 Role of MutantDx in the Global Non-Invasive Liquid Biopsy Market
    • 14.8.3 SWOT Analysis
  • 14.9 Norgen Biotek Corp
    • 14.9.1 Company Overview
    • 14.9.2 Role of Norgen Biotek Corp in the Global Non-Invasive Liquid Biopsy Market
    • 14.9.3 SWOT Analysis
  • 14.1 Nucleix Ltd.
    • 14.10.1 Company Overview
    • 14.10.2 Role of Nucleix Ltd. in the Global Non-Invasive Liquid Biopsy Market
    • 14.10.3 SWOT Analysis
  • 14.11 Oasis Diagnostics Corporation
    • 14.11.1 Company Overview
    • 14.11.2 Role of Oasis Diagnostics Corporation in the Global Non-Invasive Liquid Biopsy Market
    • 14.11.3 SWOT Analysis
  • 14.12 OraSure Technologies, Inc.
    • 14.12.1 Company Overview
    • 14.12.2 Role of OraSure Technologies, Inc. in the Global Non-Invasive Liquid Biopsy Market
    • 14.12.3 Financials
    • 14.12.4 Key Insights About Financial of the Company
    • 14.12.5 SWOT Analysis
  • 14.13 PerkinElmer Inc.
    • 14.13.1 Company Overview
    • 14.13.2 Role of PerkinElmer Inc. in the Global Non-Invasive Liquid Biopsy Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights About Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 Predicine, Inc.
    • 14.14.1 Company Overview
    • 14.14.2 Role of Predicine, Inc. in the Global Non-Invasive Liquid Biopsy Market
    • 14.14.3 SWOT Analysis
  • 14.15 QIAGEN N.V.
    • 14.15.1 Company Overview
    • 14.15.2 Role of QIAGEN N.V. in the Global Non-Invasive Liquid Biopsy Market
    • 14.15.3 Financials
    • 14.15.4 Key Insights About Financial Health of the Company
    • 14.15.5 SWOT Analysis
  • 14.16 Thermo Fisher Scientific Inc.
    • 14.16.1 Company Overview
    • 14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Non-Invasive Liquid Biopsy Market
    • 14.16.3 Financials
    • 14.16.4 Key Insights About Financial Health of the Company
    • 14.16.5 SWOT Analysis
  • 14.17 Zymo Research Corporation
    • 14.17.1 Company Overview
    • 14.17.2 Role of Zymo Research Corporation in the Global Non-Invasive Liquid Biopsy Market
    • 14.17.3 SWOT Analysis

List of Tables

  • Table 5.1: Classification Rules of IVDs under the IVDR
  • Table 5.2: Key Coverage Providers for Non-Invasive Liquid Biopsy Tests
  • Table 6.1: Likert Scale
  • Table 6.2: Impact Analysis of Market Drivers
  • Table 6.3: Impact Analysis of Market Restraints

List of Figures

  • Figure 1: U.S. National Cancer Institute (NCI), Fiscal Budget Year-on-Year, 2013-2018
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Non-Invasive Liquid Biopsy Market
  • Figure 3: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020 and 2031
  • Figure 4: Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2020 and 2031
  • Figure 5: Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020 and 2031
  • Figure 6: Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020 and 2031
  • Figure 7: Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020 and 2031
  • Figure 8: Global Non-invasive Liquid Biopsy Market Snapshot
  • Figure 2.1: Global Non-Invasive Liquid Biopsy Market Segmentation
  • Figure 3.1: Global Non-Invasive Liquid Biopsy Market: Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 4.2: Global Non-Invasive Liquid Biopsy Market: COVID-19 Impact Analysis
  • Figure 5.1: Components Considered for Clinical Evidence as per the IVDR
  • Figure 5.2: Global Non-Invasive Liquid Biopsy Market (Return on Investment (RoI) Analysis)
  • Figure 6.1: Global Cancer Burden (by Region), 2018
  • Figure 6.2: Increasing Government Spending for Healthcare, 2017
  • Figure 7.1: Share of Key Developments and Strategies, January 2017-July 2021
  • Figure 7.2: Share of Synergistic Activities (by Company), January 2017-June 2021
  • Figure 7.3: Share of Product Approvals (by Company), January 2017-July 2021
  • Figure 7.4: Number of Product Launches (by Company), January 2017-July 2021
  • Figure 7.5: Share of Acquisitions (by Company), January 2017-July 2021
  • Figure 7.6: Market Share Analysis for Global Non-Invasive Liquid Biopsy Market, $Million, 2019 and 2020
  • Figure 7.7: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Company), 2020
  • Figure 7.8: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Technology), 2020-2031
  • Figure 7.9: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Application), 2020-2031
  • Figure 8.1: Global Non-Invasive Liquid Biopsy Market (by Offering)
  • Figure 8.2: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020 and 2031
  • Figure 8.3: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020-2031
  • Figure 8.4: Global Non-Invasive Liquid Biopsy Market (by Offering), 2020 and 2031
  • Figure 8.5: Global Non-Invasive Liquid Biopsy Market (Kits), $Million, 2020-2031
  • Figure 8.6: Global Non-Invasive Liquid Biopsy Market (Assays), $Million, 2020-2031
  • Figure 8.7: Global Non-Invasive Liquid Biopsy Market (Services), $Million, 2020-2031
  • Figure 9.1: Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2020-2031
  • Figure 9.2: Global Non-Invasive Liquid Biopsy Market (by Sample), 2020 and 2031
  • Figure 9.3: Global Non-Invasive Liquid Biopsy Market (Stool), $Million, 2020-2031
  • Figure 9.4: Global Non-Invasive Liquid Biopsy Market (Urine), $Million, 2020-2031
  • Figure 9.5: Global Non-Invasive Liquid Biopsy Market (Saliva), $Million, 2020-2031
  • Figure 9.6: Global Non-Invasive Liquid Biopsy Market (Other Samples), $Million, 2020-2031
  • Figure 10.1: Global Non-Invasive Liquid Biopsy Market (by Application)
  • Figure 10.2: Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
  • Figure 10.3: Global Non-Invasive Liquid Biopsy Market (Oncology), $Million, 2020-2031
  • Figure 10.4: Global Non-Invasive Liquid Biopsy Market (Reproductive Health), $Million, 2020-2031
  • Figure 10.5: Global Non-Invasive Liquid Biopsy Market (Metabolic Disorders), $Million, 2020-2031
  • Figure 10.6: Global Non-Invasive Liquid Biopsy Market (Other Applications), $Million, 2020-2031
  • Figure 11.1: Global Non-Invasive Liquid Biopsy Market (by Technology)
  • Figure 11.2: Global Non-Invasive Liquid Biopsy Market (by Technology), 2020 and 2031
  • Figure 11.3: Global Non-Invasive Liquid Biopsy Market (PCR), $Million, 2020-2031
  • Figure 11.4: Global Non-Invasive Liquid Biopsy Market (PCR), 2020 and 2031
  • Figure 11.5: Global Non-Invasive Liquid Biopsy Market (RT-PCR, by PCR), $Million, 2020-2031
  • Figure 11.6: Global Non-Invasive Liquid Biopsy Market (dPCR, by PCR), $Million, 2020-2031
  • Figure 11.7: Global Non-Invasive Liquid Biopsy Market (Sequencing), $Million, 2020-2031
  • Figure 11.8: Global Non-Invasive Liquid Biopsy Market (Sequencing), 2020 and 2031
  • Figure 11.9: Global Non-Invasive Liquid Biopsy Market (NGS, by Sequencing), $Million, 2020-2031
  • Figure 11.10: Global Non-Invasive Liquid Biopsy Market (Sanger Sequencing, by Sequencing), $Million, 2020-2031
  • Figure 11.11: Global Non-Invasive Liquid Biopsy Market (Microarray), $Million, 2020-2031
  • Figure 11.12: Global Non-Invasive Liquid Biopsy Market (Other Technologies), $Million, 2020-2031
  • Figure 12.1: Global Non-Invasive Liquid Biopsy Market (by End User)
  • Figure 12.2: Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020-2031
  • Figure 12.3: Global Non-Invasive Liquid Biopsy Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2031
  • Figure 12.4: Global Non-Invasive Liquid Biopsy Market (Academic and Research Institutions), $Million, 2020-2031
  • Figure 12.5: Global Non-Invasive Liquid Biopsy Market (Other End Users), $Million, 2020-2031
  • Figure 13.1: Global Non-Invasive Liquid Biopsy Market (by Region): Market Snapshot
  • Figure 13.2: Global Non-Invasive Liquid Biopsy Market (by Region), $Million, 2020-2031
  • Figure 13.3: North America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.4: North America: Market Dynamics
  • Figure 13.5: North America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
  • Figure 13.6: U.S. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.7: Canada Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.8: North America Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
  • Figure 13.9: Europe Non-invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.10: Europe: Market Dynamics
  • Figure 13.11: Europe Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
  • Figure 13.12: Germany Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.13: U.K. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.14: France Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.15: Italy Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.16: Spain Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.17: Netherlands Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.18: Rest-of-Europe Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.19: Europe Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
  • Figure 13.20: Asia-Pacific Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.21: APAC Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
  • Figure 13.22: China Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.23: Japan Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.24: India Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.25: South Korea Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.26: Australia Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.27: Singapore Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.28: RoAPAC Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.29: APAC Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
  • Figure 13.30: Latin America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.31: Latin America: Market Dynamics
  • Figure 13.32: Latin America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031
  • Figure 13.33: Brazil Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.34: Mexico Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.35: RoLA Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.36: LATAM Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
  • Figure 13.37: Rest-of-the-World Non-Invasive Liquid Biopsy Market, $Million, 2020-2031
  • Figure 13.38: Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031
  • Figure 14.1: Total Number of Companies Profiled
  • Figure 14.2: Bio-Techne Corporation: Service Portfolio
  • Figure 14.3: Bio-Techne Corporation: Overall Financials, 2018-2020
  • Figure 14.4: Bio-Techne Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.5: Bio-Techne Corporation: Revenue (by Region), 2018-2020
  • Figure 14.6: Bio-Techne Corporation: R&D Expenditure, 2018-2020
  • Figure 14.7: Bio-Techne Corporation: SWOT Analysis
  • Figure 14.8: Endress + Hauser Group: Product Portfolio
  • Figure 14.9: Endress + Hauser Group: Overall Financials, 2018-2020
  • Figure 14.10: Endress + Hauser Group: Revenue (by Segment), 2018-2020
  • Figure 14.11: Endress + Hauser Group: Revenue (by Region), 2018-2020
  • Figure 14.12: Endress + Hauser Group: R&D Expenditure, 2018-2020
  • Figure 14.13: Endress + Hauser Group: SWOT Analysis
  • Figure 14.14: Exact Sciences Corporation: Service Portfolio
  • Figure 14.15: Exact Sciences Corporation: Overall Financials, 2018-2020
  • Figure 14.16: Exact Sciences Corporation: Revenue (by Segment), 2018-2020

Figure14.17: Exact Sciences Corporation: Revenue (by Region), 2018-2020

  • Figure 14.18: Exact Sciences Corporation: R&D Expenditure, 2018-2020
  • Figure 14.19: Exact Sciences Corporation: SWOT Analysis
  • Figure 14.20: Lonza Group AG: Product Portfolio
  • Figure 14.21: Lonza Group AG: Overall Financials, 2018-2020
  • Figure 14.22: Lonza Group AG: Revenue (by Segment), 2018-2020
  • Figure 14.23: Lonza Group AG: Revenue (by Region), 2018-2020
  • Figure 14.24: Lonza Group AG: R&D Expenditure, 2018-2020
  • Figure 14.25: Lonza Group AG: SWOT Analysis
  • Figure 14.26: MDxHealth: Service Portfolio
  • Figure 14.27: MDxHealth: Overall Financials, 2018-2020
  • Figure 14.28: MDxHealth: Revenue (by Segment), 2018-2020
  • Figure 14.29: MDxHealth: Revenue (by Region), 2018-2020
  • Figure 14.30: MDxHealth: R&D Expenditure, 2018-2020
  • Figure 14.31: MDxHealth: SWOT Analysis
  • Figure 14.32: Merck KGaA: Product Portfolio
  • Figure 14.33: Merck KGaA: Overall Financials, 2018-2020
  • Figure 14.34: Merck KGaA: Revenue (by Segment), 2018-2020
  • Figure 14.35: Merck KGaA: Revenue (by Region), 2018-2020
  • Figure 14.36: Merck KgaA: R&D Expenditure, 2018-2020
  • Figure 14.37: Merck KGaA: SWOT Analysis
  • Figure 14.38: MutantDx: Product Portfolio
  • Figure 14.39: MutantDx: SWOT Analysis
  • Figure 14.40: Norgen Biotek Corp: Product Portfolio
  • Figure 14.41: Norgen Biotek Corp: SWOT Analysis
  • Figure 14.42: Nucleix Ltd.: Product Portfolio
  • Figure 14.43: Nucleix Ltd.: SWOT Analysis
  • Figure 14.44: Oasis Diagnostics Corporation: Product Portfolio
  • Figure 14.45: Oasis Diagnostics Corporation: SWOT Analysis
  • Figure 14.46: OraSure Technologies, Inc.: Product Portfolio
  • Figure 14.47: OraSure Technologies, Inc.: Overall Financials, 2018-2020
  • Figure 14.48: OraSure Technologies, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.49: OraSure Technologies, Inc.: Revenue (by Molecular Solutions), 2019-2020
  • Figure 14.50: OraSure Technologies, Inc.: Revenue (by Region), 2018-2020
  • Figure 14.51: OraSure Technologies, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.52: OraSure Technologies, Inc.: SWOT Analysis
  • Figure 14.53: PerkinElmer Inc.: Product Portfolio
  • Figure 14.54: PerkinElmer Inc.: Overall Financials, 2018-2020
  • Figure 14.55: PerkinElmer Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.56: PerkinElmer Inc.: Revenue (by Region), 2018-2020
  • Figure 14.57: PerkinElmer Inc.: R&D Expenditure, 2018-2020
  • Figure 14.58: PerkinElmer Inc.: SWOT Analysis
  • Figure 14.59: Predicine, Inc.: Service Portfolio
  • Figure 14.60: Predicine, Inc.: SWOT Analysis
  • Figure 14.61: QIAGEN N.V.: Product Portfolio
  • Figure 14.62: QIAGEN N.V.: Overall Financials, 2018-2020
  • Figure 14.63: QIAGEN N.V.: Revenue (by Segment), 2018-2020
  • Figure 14.64: QIAGEN N.V.: Revenue (by Region), 2018-2020
  • Figure 14.65: QIAGEN N.V.: R&D Expenditure, 2018-2020
  • Figure 14.66: QIAGEN N.V.: SWOT Analysis
  • Figure 14.67: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 14.68: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
  • Figure 14.69: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
  • Figure 14.70: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
  • Figure 14.71: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 14.72: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 14.73: Zymo Research Corporation: Product Portfolio
  • Figure 14.74: Zymo Research Corporation: SWOT Analysis